(NASDAQ: NVAX) Novavax's forecast annual revenue growth rate of -46.76% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.88%.
Novavax's revenue in 2025 is $1,078,718,000.On average, 10 Wall Street analysts forecast NVAX's revenue for 2025 to be $178,663,809,500, with the lowest NVAX revenue forecast at $162,421,645,000, and the highest NVAX revenue forecast at $206,113,067,505. On average, 10 Wall Street analysts forecast NVAX's revenue for 2026 to be $74,277,042,475, with the lowest NVAX revenue forecast at $43,158,679,509, and the highest NVAX revenue forecast at $169,893,040,670.
In 2027, NVAX is forecast to generate $42,591,827,968 in revenue, with the lowest revenue forecast at $21,488,383,634 and the highest revenue forecast at $67,432,594,355.